- Company reports positive clinical results from HERHEART(TM) and Fuel4Thought(TM), produced by subsidiaries BergaMet North America and Ultimate Brain Nutrients
- Purchase agreement with Xymogen(R) for BergaMet North America’s Citrus Bergamot SuperFruit(TM) expected to generate significant revenue and distribution opportunities nationwide
- The global market for botanical and plant-derived drugs was valued at $29.4 billion in 2017 and is expected to reach $39.6 billion by 2022
- Healthy Extracts is nearly debt-free with minimal overhead costs
Through a growing portfolio of wholly owned subsidiaries, Healthy Extracts (OTCQB: HYEX) (formerly Grey Cloak Tech) is engaged in proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. Through its unique assets and operations of subsidiaries BergaMet North America and Ultimate Brain Nutrients (“UBN”), the company aims to offer better lifestyle opportunities while advancing its market position in the health industry.
The company has recently announced promising results of clinical studies for two leading products: BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster.
HERHEART(TM) is an exclusive natural supplement that is scientifically formulated specifically for women to support cardiovascular health, including perimenopausal symptoms. The study was conducted in 35 postmenopausal women with sexual dysfunction at the University Magna Graecia of Caranzaro in Italy. Results indicated that patients who were administered HERHEART(TM) reported a 40 percent decrease in mood swings and 60 percent reduction in hot flashes, along with a 45 percent increase in energy and a 40 to 70 percent increase in desire and arousal. The supplement was also shown to have beneficial effects in what regards fat metabolizing, lower cholesterol levels and anti-inflammatory action (https://ibn.fm/c2yTR).
Duke Pitts, CEO of BergaMet North America, explained that HERHEART(TM) was specifically designed to fill the void in heart health products designed for women, in the context in which cardiovascular disease is the number one cause of death for women in the U.S. “Not only does HERHEART assist in metabolic syndrome challenges, it also provides continued support for women as they mature. There is no other product that focuses directly on women, combines natural ingredients, and has the clinical studies to confirm its effectiveness,” Pitts said.
The company expects HERHEAT(TM) to become one of its top selling products, while providing an exclusive market position. Aiding in the product’s promotion is internationally renowned Dr. Nesochi Okeke-Igbokwe MD., M.S, who recently joined the company’s Medical Advisory Board. Dr. Nesochi is a respected international health expert and trusted media resource.
Shortly after releasing the results about HERHEART(TM), the company’s UBN subsidiary released its study of Fuel4Thought(TM) Brain Booster, showing impressive results in brain activation, sports vision, hand to eye coordination, and auditory reaction time. The results were presented by Dr. Neil Wolkadoff and Dr. Gerald Haase at the 2020 meeting of the American College of Sports Medicine. The prospective, randomized, double-blind, and placebo-controlled trial was completed at the Colorado Center for Health and Sport Science.
Renowned Iron Man Triathlete and Medical Advisory Board President Dr. James Rouse explained that the study of Fuel4Thought(TM) shows that it improves brain activity energy by 49%, improves overall sports vision by 18%, improves auditory reaction time by 13%, and improves reaction time and hand-eye coordination by 24% (https://ibn.fm/4q3Oc).
Rounding out a successful 2020, BergaMet North America entered into an exclusive performance-driven agreement with Xymogen(R) for the purchase of BergaMet North America’s Citrus Bergamot SuperFruit(TM). The agreement between BergaMet North America and the leading manufacturer and distributor of clinical-grade nutraceuticals has been three years in the making. Xymogen(R) is currently selling and distributing proprietary formulations of BergaCor(TM) and BergaCorPlus(TM) to over 20,000 doctors in their network (https://ibn.fm/iOSZb).
Discussing the partnership with Xymogen(R), Pitts said it is a clear example of BergaMet North America’s strategic B2B goal of a continuing growth strategy. “We are very excited as this agreement provides significant revenue generation and distribution through Xymogen’s national market footprint,” Pitts said.
This partnership is expected to help BergaMet and by extension the company solidify their position on the global market for botanical and plant-derived drugs, which was valued a $29.4 billion in 2017. The market is expected to continue growing and reach an estimated $39.6 billion by 2022, marking a CAGR of 6.1 percent (https://ibn.fm/DGrVD).
The company’s focus is currently on the categories of heart and brain health, liver disease, women’s health, and immune function, resulting in a potential target audience of more than two hundred million people in the United States. The company experienced large growth over the last year and is operating nearly debt-free with minimal overhead costs. Lead by a strong and experienced executive team, the company plans to launch its proprietary products with an aggressive revenue outlook in mind and focus on continuing its growth strategy through 2021 and beyond.
For more information, visit the company’s website at www.HealthyExtractsInc.com.
NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.